Shares of Australia's HealthLinx shot up after the biotech announced that its diagnostic test for ovarian cancer outperformed the diagnostic tool now in use. Investigators said that OvPlex significantly reduced the number of diagnostic errors made in analyzing blood samples. Most women aren't diagnosed with ovarian cancer until the disease has progressed to a late stage, severely reducing their odds of surviving the disease for more than a few years. Story